(Q42644963)

4 November 2017

title

Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: II. Clinical relevance (English)

1 reference

4 November 2017

1 reference

Zachary AA

1

1 reference

4 November 2017

Ratner LE

2

1 reference

4 November 2017

Graziani JA

3

1 reference

4 November 2017

Lucas DP

4

1 reference

4 November 2017

Delaney NL

5

1 reference

4 November 2017

Leffell MS

6

1 reference

4 November 2017

publication date

1 March 2001

1 reference

4 November 2017

1 reference

4 November 2017

volume

62

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

236-246

1 reference

Public antigenic determinant on a family of HLA-B molecules

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Monoclonal Antibodies as Tools to Analyze the Serological and Genetic Complexities of Major Transplantation Antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

HLA alloantibodies and the mechanism of the antiglobulin-augmented lymphocytotoxicity procedure

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

HLA antibody screening: comparison of a solid phase enzyme-linked immunoassay with antiglobulin-augmented lymphocytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Antibody screening by enzyme-linked immunosorbent assay using pooled soluble HLA in renal transplant candidates

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Characterization of HLA class I specific antibodies by ELISA using solubilized antigen targets: I. Evaluation of the GTI QuikID assay and analysis of antibody patterns

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

HLA and cross-reactive antigen group matching for cadaver kidney allocation

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Effect of Bw4 and Bw6 epitope mismatches on antibody production, acute and chronic rejection, and graft survival in renal allografts

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Differences in anti-CREG antibody formation between transplanted and nontransplanted renal patients

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Development of anti-HLA-antibodies against intra-CREG-mismatches in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

HLA class I and class II antibodies: monitoring before and after kidney transplantation and their clinical relevance

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

The clinical importance of choosing the right assay for detection of HLA-specific donor-reactive antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0198-8859%2800%2900253-6

7 January 2021

10.1016/S0198-8859(00)00253-6

Identifiers

DOI

1 reference

4 November 2017

1 reference